IRIS
BELLI, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 377
EU - Europa 244
NA - Nord America 230
SA - Sud America 16
AF - Africa 2
OC - Oceania 1
Totale 870
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 277
US - Stati Uniti d'America 227
IT - Italia 118
CN - Cina 63
FI - Finlandia 44
DE - Germania 37
NL - Olanda 23
BR - Brasile 14
HK - Hong Kong 14
GB - Regno Unito 10
IN - India 5
KR - Corea 5
FR - Francia 3
LT - Lituania 3
AZ - Azerbaigian 2
CA - Canada 2
IE - Irlanda 2
PE - Perù 2
AU - Australia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GE - Georgia 1
GR - Grecia 1
ID - Indonesia 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
PH - Filippine 1
PK - Pakistan 1
PL - Polonia 1
PT - Portogallo 1
TW - Taiwan 1
UZ - Uzbekistan 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 870
Salva come PNG Salva come JPEG
Città #
Singapore 111
Boardman 106
Florence 48
Shanghai 42
Helsinki 39
Ogden 21
Munich 17
Falkenstein 16
Hong Kong 14
Amsterdam 12
Milan 10
Rome 10
Lappeenranta 5
London 5
Seoul 5
Kilburn 4
Paola 4
Frankfurt am Main 3
São Paulo 3
Verona 3
Baku 2
Bologna 2
Brescia 2
Campodarsego 2
Dublin 2
Guangzhou 2
Gurugram 2
Hangzhou 2
Jiaxing 2
Lima 2
Los Angeles 2
Lyon 2
Nashik 2
Rende 2
San Giovanni Lupatoto 2
Seattle 2
Toronto 2
Alessandria 1
Ashburn 1
Athens 1
Bishkek 1
Bolzano 1
Brasília 1
Campinas 1
Campo Largo 1
Chelsea 1
Cosenza 1
Governador Valadares 1
Haifa 1
Heze 1
Islamabad 1
Manila 1
Maracaju 1
Marseille 1
Mauá 1
Melbourne 1
Messina 1
Naples 1
New York 1
Newark 1
Nova Friburgo 1
Oslo 1
Plainsboro 1
Prato 1
Rocca d'Arazzo 1
Santa Maria 1
Santo André 1
Sesto San Giovanni 1
Sete Lagoas 1
Shenzhen 1
Stellenbosch 1
Syracuse 1
Taipei 1
Tashkent 1
Tbilisi 1
Valinhos 1
Vientiane 1
Warsaw 1
Zagazig 1
Totale 554
Salva come PNG Salva come JPEG
Nome #
Variant allele frequency: a decision-making tool in precision oncology? 66
Expression of the oncoproteins p16, p53 and Ki67 as predictive value in the differentiation of low-grade intracervical neoplasms of high and low risk 36
Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women 31
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 28
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 27
Homologous recombination deficiency in triple negative breast cancer 25
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 25
(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized phase II trial 24
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research 24
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 23
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 23
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: Not just a case? 23
Adjuvant treatment in biliary tract cancer: To treat or not to treat? 22
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) 22
Clinical significance of skin toxicity due to EGFR-targeted Therapies 22
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial 22
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors 22
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity 21
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 20
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 20
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 20
Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature 20
Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: Focus on TLR9 agonists, IMiDs and NGR-TNF 19
Malignant pleural mesothelioma: Current treatments and emerging drugs 19
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 18
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 18
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 18
Will antiangiogenic agents be a future for mesothelioma therapy? 18
Antiangiogenic strategies in breast cancer management 18
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 17
Targeting the microenvironment in solid tumors 17
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting 17
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data 17
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 16
Neo-adjuvant and adjuvant chemotherapy of gastric cancer 16
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 15
Progresses toward precision medicine in RET-altered solid tumors 15
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer 15
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach 15
Neoadjuvant therapy in resectable pancreatic cancer: A critical review 14
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 13
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 13
Translational therapies for malignant pleural mesothelioma 12
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma 12
Role of taxanes in pancreatic cancer 11
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies 11
Unity is strength: One, two, or more drugs against advanced pancreatic cancer? 11
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 10
Mesoteliona Pleurico 10
Second-line therapy in advanced biliary tract cancer: What should be the standard? 10
Malignant Mesothelioma 9
Tumori del polmone 9
Mesotelioma Pleurico 4
Totale 1.003
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.057
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.057
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023194 0 0 0 0 0 0 0 0 140 5 49 0
2023/2024200 5 1 27 8 15 6 8 32 35 13 14 36
2024/2025609 36 114 23 42 47 106 15 70 155 1 0 0
Totale 1.003